New device indications: practice and cost implications in Europe
New device indications: practice and cost implications in Europe
The potential clinical value of implantable devices, for both diagnostic and therapeutic uses in cardiology practice, has increased greatly with technical innovation. This coupled with an increased recipient population size (as the population ages) and increased referral rates (as that population and its healthcarers are educated), has increased the demand for such devices and the associated economic burden is impacting on healthcare resources. Although there is a commonality of approach to clinical practice in Europe, aided by the publication of European guidelines, the implementation of these is hindered by the need to overcome national obstacles, particularly for new indications for established therapies and for innovative therapies. Cost efficacy assessments and evidence-based medicine are blurred and used as rationing tools. National inequalities and disparate healthcare systems will become divisive in a European theatre that is otherwise seeing greater political and economic integration. There needs to be a mature and honest debate on how to bring the benefits of implantable device medical technology to the patient population which will benefit.
pacemaker, artificial, cost-benefit analysis, economics, defibrillators, implantable, practice guidelines, education, medical, syncope, heart arrest, tachycardia, ventricular, arrhythmia, ventricular fibrillation, cardiac resynchronization therapy, health services
49-53
Morgan, J.M.
e1a187e2-3fae-414d-86b6-dfe336ec94f9
2003
Morgan, J.M.
e1a187e2-3fae-414d-86b6-dfe336ec94f9
Morgan, J.M.
(2003)
New device indications: practice and cost implications in Europe.
Cardiac Electrophysiology Review, 7 (1), .
Abstract
The potential clinical value of implantable devices, for both diagnostic and therapeutic uses in cardiology practice, has increased greatly with technical innovation. This coupled with an increased recipient population size (as the population ages) and increased referral rates (as that population and its healthcarers are educated), has increased the demand for such devices and the associated economic burden is impacting on healthcare resources. Although there is a commonality of approach to clinical practice in Europe, aided by the publication of European guidelines, the implementation of these is hindered by the need to overcome national obstacles, particularly for new indications for established therapies and for innovative therapies. Cost efficacy assessments and evidence-based medicine are blurred and used as rationing tools. National inequalities and disparate healthcare systems will become divisive in a European theatre that is otherwise seeing greater political and economic integration. There needs to be a mature and honest debate on how to bring the benefits of implantable device medical technology to the patient population which will benefit.
This record has no associated files available for download.
More information
Published date: 2003
Keywords:
pacemaker, artificial, cost-benefit analysis, economics, defibrillators, implantable, practice guidelines, education, medical, syncope, heart arrest, tachycardia, ventricular, arrhythmia, ventricular fibrillation, cardiac resynchronization therapy, health services
Identifiers
Local EPrints ID: 25827
URI: http://eprints.soton.ac.uk/id/eprint/25827
ISSN: 1385-2264
PURE UUID: 09f38fc8-4c8f-4150-9cb5-590c6c456c57
Catalogue record
Date deposited: 20 Apr 2006
Last modified: 08 Jan 2022 15:52
Export record
Contributors
Author:
J.M. Morgan
Download statistics
Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.
View more statistics